A multiscale systems model of bone health and mineral homeostasis
================
Metrum Research Group

- [Predicting nonlinear BMD changes over
  time](#predicting-nonlinear-bmd-changes-over-time)
  - [`OpenBoneMin` model](#openbonemin-model)
  - [Generate the dosing regimens](#generate-the-dosing-regimens)
  - [Publication figure 3: CTx vs
    time](#publication-figure-3-ctx-vs-time)
  - [Publication figure 4: BSAP vs
    time](#publication-figure-4-bsap-vs-time)
  - [Publication figure 5: LS BMD vs
    time](#publication-figure-5-ls-bmd-vs-time)
  - [Publication figure 6: TGF-$\beta$ vs
    time](#publication-figure-6-tgf-beta-vs-time)
- [Using `OpenBoneMin`](#using-openbonemin)
  - [Install from GitHub as an R
    package](#install-from-github-as-an-r-package)
  - [Load the OpenBoneMin model](#load-the-openbonemin-model)
  - [Teriparatide example](#teriparatide-example)
  - [Denosumab example](#denosumab-example)

# Predicting nonlinear BMD changes over time

**Predicting Nonlinear Changes in Bone Mineral Density Over Time Using a
Multiscale Systems Pharmacology Model**

Peterson MC, Riggs MM. CPT Pharmacometrics Syst Pharmacol. 2012 Nov
14;1:e14. doi: 10.1038/psp.2012.15. PubMed PMID: 23835796; PubMed
Central PMCID: PMC3600731 [PubMed
Citation](https://www.ncbi.nlm.nih.gov/pubmed/23835796) / [Free Full
Text](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600731)

- Bone is constantly being remodeled, constantly turning over. This
  remodeling process consists of breaking down old bone and building up
  new bone

- *Osteoclasts* are cells that function to disassemble bone (resorption)
  and *osteoblasts* are cells that function to synthesize or build new
  bone

- One therapeutic strategy for osteoporosis (porous bone) is to inhibit
  osteoclast activity and thus inhibit the bone resorption activity  

- **Denosumab** decreases osteoclast activity by preventing maturation
  of pre-osteoclasts into fully-functional osteoclast cells

- The goal of the modeling was to predict nonlinear changes in lumbar
  spine (LS) bone mineral density (BMD) over 48 months of denosumab
  treatment under different dosing regimens.

- **LSBMD** was modeled as a function of bone turnover markers

- CTx: C-telopeptide, a marker for osteoclast function

- BSAP: bone-specific alkaline phosphatase, a marker for osteoblast
  function

- Our **simulation objective** is to recreate figures 3, 4, 5, and 6
  from the publication. This will show the changes in CTx and BSAP and
  the subsequent changes in BMD under the model.

## `OpenBoneMin` model

**Background and Motivation**

The model was originally developed to describe the bone marker changes
associated with denosumab administration from a then ongoing clinical
trial. Associated changes in serum calcium and PTH were also considered
of interest at the time and so justified the development of a ‘systems’
model that included bone remodeling and bone mineral (calcium and
phosphate) homeostatic mechanisms. Other therapeutics (e.g.,
teriparatide) and disease states (kidney failure, parathyroid-related
abnormalities) were also considered at the time to further inform the
parameterization and estimation of the model (Peterson and Riggs, Bone
2010).

**Load the model**

We will use the `OpenBoneMin` package to simulate. See below for details
on installing this package from GitHub.

``` r
library(OpenBoneMin)
library(tidyverse)
theme_set(theme_bw() + theme(legend.position = "top"))
```

``` r
mod <- BoneMin()
```

## Generate the dosing regimens

**60 mg every 6 months x 8**

``` r
month <- 24*28

regi <- function(x) factor(x, labels = c("60 mg Q6M", "14 mg Q6M", 
                                         "30 mg Q3M", "210 mg Q6M"))
xscale <- scale_x_continuous(
  breaks = c(0, 3, 6, 12, 18, 24, 36, 48), 
  limits = c(0, 48)
)
```

``` r
e1 <- ev(amt = 60, ii = 6*month, addl = 7)
e1
```

    . Events:
    .   time amt   ii addl cmt evid
    . 1    0  60 4032    7   1    1

**14 mg every 6 months x4, then 60 mg every 6 months x4**

``` r
e2 <- ev_seq(
  mutate(e1, amt = 14, addl = 3),
  mutate(e1, addl = 3)
)
e2
```

    . Events:
    .    time amt   ii addl cmt evid
    . 1     0  14 4032    3   1    1
    . 2 16128  60 4032    3   1    1

**30 mg every 3 months for 8 doses and changed to 60 mg Q6M starting on
month 36**

``` r
e3a <- ev(amt = 30, ii = 3*month, addl = 7)
e3b <- mutate(e1, addl = 1) %>% as.ev()
e3 <- seq(e3a, wait = 12*month, e3b)
e3
```

    . Events:
    .    time amt   ii addl cmt evid
    . 1     0  30 2016    7   1    1
    . 2 24192  60 4032    1   1    1

**210 mg every 6 months x4 then DC**

``` r
e4 <- mutate(e1, amt = 210, addl = 3)
e4
```

    . Events:
    .   time amt   ii addl cmt evid
    . 1    0 210 4032    3   1    1

**Create one single data set from which to simulate**

``` r
data <- as_data_set(e1, e2, e3, e4)

data
```

    .   ID  time cmt evid amt   ii addl
    . 1  1     0   1    1  60 4032    7
    . 2  2     0   1    1  14 4032    3
    . 3  2 16128   1    1  60 4032    3
    . 4  3     0   1    1  30 2016    7
    . 5  3 24192   1    1  60 4032    1
    . 6  4     0   1    1 210 4032    3

``` r
out <- 
  mod %>%
  mrgsim(data = data, end = 48*month, delta = 24) %>% 
  mutate(ID = regi(ID), Month = time/month)
```

## Publication figure 3: CTx vs time

Shown here is the percent change from baseline value for osteoclasts
(via CTx)

``` r
ggplot(out) + 
  geom_line(aes(x = Month, y = OCchange, col = factor(ID)), lwd = 1) + 
  facet_grid(~ID) + 
  geom_hline(yintercept = 100, lty = 2) +
  scale_y_log10(breaks = c(10,30,100,300), limits = c(5,300)) + 
  geom_vline(xintercept = c(24,36), lty = 3) + xscale
```

![](img/OpenBoneMin-unnamed-chunk-11-1.png)<!-- -->

## Publication figure 4: BSAP vs time

Shown here is the percent change from baseline value for osteoblasts
(via BSAP)

``` r
ggplot(out) + 
  geom_line(aes(x = Month, y = OBchange, col = factor(ID)), lwd = 1) + 
  geom_hline(yintercept = 100, lty = 2) +
  facet_grid(~ID) + 
  scale_y_log10(breaks = c(10,30,100,300), limits = c(5,300)) +
  geom_vline(xintercept = c(24,36), lty = 3) + xscale
```

![](img/OpenBoneMin-unnamed-chunk-13-1.png)<!-- -->

## Publication figure 5: LS BMD vs time

Shown here is the percent change from baseline value for lumbar spine
BMD

``` r
ggplot(out) + 
  geom_line(aes(x = Month, y = BMDlsDENchange, col = factor(ID)), lwd = 1) + 
   geom_vline(xintercept = c(24,36), lty = 3) +
  facet_grid(~ID) + xscale
```

![](img/OpenBoneMin-unnamed-chunk-14-1.png)<!-- -->

## Publication figure 6: TGF-$\beta$ vs time

- Solid lines are **active** TGF-$\beta$
- Dashed lines are **latent** TGF-$\beta$

``` r
out <- 
  out %>%
  group_by(ID) %>%
  mutate(ATGF = 100*TGFBact/first(TGFBact), LTGF = 100*TGFB/first(TGFB)) %>%
  ungroup

ggplot(out) + 
  geom_line(aes(x = Month, y = ATGF, col = factor(ID)), lwd = 1) + 
  geom_line(aes(x = Month, y = LTGF), col = "black", lty = 2, lwd = 0.6) + 
  facet_grid(~ID) + 
  geom_vline(xintercept = c(24,36), lty = 3) + xscale +
  scale_y_continuous(breaks = c(0,25,50,75,100,150,225), limits = c(0,225)) 
```

![](img/OpenBoneMin-unnamed-chunk-15-1.png)<!-- -->

# Using `OpenBoneMin`

This section goes over how to get and use `OpenBoneMin`.

## Install from GitHub as an R package

``` r
remotes::install_github("metrumresearchgroup/OpenBoneMin")
```

## Load the OpenBoneMin model

``` r
mod <- BoneMin()
```

## Teriparatide example

- Teriparatide is a recombinant parathyroid (PTH) hormone, containing
  only the first 84 amino acid residues
- Teriparatide doses are administered subcutaneously and are absorbed
  into the PTH compartment; so teriparatide is considered equivalent to
  PTH
- We’ll give either 20 or 40 micrograms SQ daily for 10 doses

``` r
out <- sim_teri(dose = c(20,40), dur = 9)

out
```

    . Model:  OpenBoneMin 
    . Dim:    4804 x 4 
    . Time:   0 to 240 
    . ID:     2 
    .     ID time PTHpm   CaC
    . 1:   1  0.0  3.85 2.350
    . 2:   1  0.0  3.85 2.350
    . 3:   1  0.1 19.59 2.351
    . 4:   1  0.2 26.29 2.352
    . 5:   1  0.3 28.62 2.353
    . 6:   1  0.4 28.87 2.354
    . 7:   1  0.5 28.17 2.355
    . 8:   1  0.6 27.04 2.356

PTH profiles for the 20 and 40 microgram doses

``` r
plot(out, PTHpm ~ time|ID, scales = "same")
```

![](img/OpenBoneMin-unnamed-chunk-19-1.png)<!-- -->

Calcium profiles for the 20 and 40 microgram doses

``` r
plot(out, CaC~time)
```

![](img/OpenBoneMin-unnamed-chunk-20-1.png)<!-- -->

## Denosumab example

- Denosumab is a human monoclonal antibody that binds RANK ligand
  (RANKL), preventing the formation of RANK/RANKL complex and subsequent
  simulation of osteoclast maturation
- The labeled dose for treatment of osteoporosis is 60 mg SQ every 6
  months

``` r
out <- sim_denos(dose = c(14,30,60,210)) %>% filter_sims(DENCP > 1e-3)
```

Plot the denosumab concentration versus time

``` r
plot(out, DENCP ~.,  scales = list(y = list(log = TRUE)))
```

![](img/OpenBoneMin-unnamed-chunk-22-1.png)<!-- -->

Plot the percent change in lumbar spine BMD versus time

``` r
plot(out, BMDlsDENchange ~ .)
```

![](img/OpenBoneMin-unnamed-chunk-23-1.png)<!-- -->
